SCHEMBL6891192

SCHEMBL6891192

CC(=O)SCCN(CCc1ccccc1)C(=O)N[C@@H](Cc1ccc([N+](=O)[O-])cc1)C(=O)N1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
P2RX7 Q99572 1/20 0.41
ALDH1A1 P00352 6/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CTSL P07711 2/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MMP8 P22894 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
CTSS P25774 1/20 0.38
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27559934 1.00 MAPT (0.41) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL27538398 0.92 ALDH1A1 (0.47) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL6895844 0.92 ALDH1A1 (0.47) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL27541548 0.92 FPR2 (0.43) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL6895842 0.92 FPR2 (0.43) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL6896529 0.91 P2RX7 (0.43) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL7677851 0.91 P2RX7 (0.43) MAPTP2RX7ALDH1A1CYP2C19HTT
SCHEMBL27538402 0.90 ALDH1A1 (0.47) MAPTP2RX7ALDH1A1CYP2C19MMP1
SCHEMBL6895635 0.90 ALDH1A1 (0.47) MAPTP2RX7ALDH1A1CYP2C19MMP1
SCHEMBL6897992 0.89 P2RX7 (0.43) MAPTP2RX7ALDH1A1CYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH MAPT 2496/4885P2RX7 2738/4885ALDH1A1 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.